Edgar Filing: ReWalk Robotics Ltd. - Form 4

ReWalk Ro Form 4 May 27, 20												
FORM A										OMB APPROVAL		
Washington, D.C. 20549						OMMISSION	OMB Number:	3235-0287				
if no lo subject Section Form 4	to SIAIE									January 31, 2005 I average burs per 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type	e Responses)											
Weisman Wayne Symb			Symbol	Issuer Name and Ticker or Trading bol Walk Robotics Ltd. [RWLK]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First)	(Middle)			Transaction			(Chec	k all applicat	ble)		
C/O REWALK ROBOTICS, LTD., 3 05/25/2016 Officer (give title							0% Owner ther (specify					
				If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(M YOKNEAM ILIT, L3 20692203				ر 				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Ta	ble I - Non	-Derivativ	e Secu	ırities Acq	uired, Disposed o	f, or Benefici	ally Owned		
1.Title of Security (Instr. 3)	curity (Month/Day/Year) Execution Date, if			3. 4. Securities Acquired (A) Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)				Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Ordinary Shares, par value NIS 0.01 per share	05/25/2016			S	12,022 (1)	D	\$	1,732,530	I	By partnership $\frac{(3)}{2}$		
Ordinary Shares, par value NIS 0.01 per share	05/26/2016			S	15,000 (4)	D	\$ 8.6071 (5)	1,717,530	I	By partnership (3) (6) (7)		
Ordinary Shares,								6,022 <u>(8)</u>	Ι	ESOP		

par value NIS 0.01 per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Weisman Wayne C/O REWALK ROBOTICS, LTD. 3 HATNUFA ST., P.O. BOX 161 YOKNEAM ILIT, L3 20692203	Х	Х					
Signatures							
/s/ Kevin Hershberger, as attorney-in-fact		05/27/2016	5				
**Signature of Reporting Person		Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The disposed of securities consist of 9,012 Ordinary Shares sold by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and 3,010 shares sold by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife Israel").

(2)

Edgar Filing: ReWalk Robotics Ltd. - Form 4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.7000 to \$8.9600, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

The Reporting Person is a director of SCP Vitalife II GP, Ltd. ("SCP Vitalife GP"), which is the sole general partner of SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"). SCP Vitalife Associates is the sole general partner of each of SCP Vitalife and SCP Vitalife

- (3) Israel, the direct beneficial owner of the Ordinary Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, except to the extent of his pecuniary interest therein.
- (4) The disposed of securities consist of 11,244 Ordinary Shares sold by SCP Vitalife and 3,756 shares sold by SCP Vitalife Israel.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from

(5) \$8.6000 to \$8.6600, inclusive. The reporting person undertakes to provide to ReWalk, any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.

As of May 27, 2016, SCP Vitalife Associates, as the general partner of SCP Vitalife and SCP Vitalife Israel, may be deemed to beneficially own 1,575,004 Ordinary Shares, which consist of 1,180,665 and 394,339 Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, respectively. SCP Vitalife GP is the general partner of SCP Vitalife Associates and, as such, shares voting and dispositive

(6) Vitame Israel, respectively. SCF Vitame OF is the general parties of SCF Vitame Associates and, as such, shares voting and dispositive power over, and may be deemed to beneficially own, the Ordinary Shares held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own 1,717,530 Ordinary Shares, which consist of the Ordinary Shares as set forth in footnote (7) to this Form 4.

As of May 27, 2016, consists of 1,575,004 Ordinary Shares held by the foregoing entities due to the Reporting Person serving as a director of SCP Vitalife GP, as well as (i) 62,006 Ordinary Shares held by Vitalife Partners (Overseas) L.P., (ii) 20,506 Ordinary Shares held by Vitalife Partners (Israel) L.P., (iii) 20,733 Ordinary Shares held by Vitalife Partners (D.C.M) L.P. ("Vitalife Partners DCM", and

(7) together with Vitalife Partners (Overseas) L.P. and Vitalife Partners (Israel) L.P., the "Vitalife I Entities") and (iv) 39,281 Ordinary Shares currently held by the Office of the Chief Scientist of the State of Israel ("OCS"), that the Vitalife I Entities have the right to acquire from the OCS, due to the Reporting Person serving as a director of Vitalife Life Sciences Ltd., the general partner of Vitalife Partners Management L.P., which is the general partner of each of the Vitalife I Entities.

Represents 6,022 ordinary shares issuable upon the vesting of restricted stock units ("RSUs") granted on December 15, 2014 under the ReWalk 2014 Equity Incentive Plan. One-third, or 2,007 Ordinary Shares, of the RSUs vested on the first anniversary of the date of grant

(8) Reward 2014 Equity incentive rial. One-unit, or 2,007 Ordinary Shares, of the RSOS vested on the first antiversary of the date of grant.
 (8) and the remaining RSUs vest in equal quarterly installments of 501 Ordinary Shares each starting one quarter after the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.